Product
AK130
1 clinical trial
1 indication
Indication
Advanced Malignant TumorsClinical trial
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AK130 (TIGIT/TGF-β Bifunctional Fusion Protein) in Patients With Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2024-01-01